Denali Therapeutics (DNLI) Cash from Financing Activities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Cash from Financing Activities data on file, last reported at $219.0 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 5922.54% year-over-year to $219.0 million in Q1 2026; TTM through Mar 2026 was $412.0 million, a 2187.98% increase from a year earlier, with the FY2025 full-year figure at $189.2 million, down 60.93% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $219.0 million, up from $192.1 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for DNLI reached as high as $500.3 million in Q1 2024 and fell as low as -$18.6 million in Q3 2024.
• Historically, Cash from Financing Activities has averaged $71.8 million across 5 years, with a median of $4.4 million in 2022.
• On a YoY basis, Cash from Financing Activities climbed as much as 31089.21% in 2024 and fell as far as 844.74% in 2024.
• Year by year, Cash from Financing Activities stood at $299.7 million in 2022, then plunged by 98.43% to $4.7 million in 2023, then slumped by 188.59% to -$4.2 million in 2024, then jumped by 4709.72% to $192.1 million in 2025, then advanced by 14.01% to $219.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $219.0 million in Q1 2026, $192.1 million in Q4 2025, and -$778000.0 in Q3 2025.